Shares of MacroGenics Inc (NASDAQ:MGNX) have been assigned a consensus rating of “Buy” from the fourteen ratings firms that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $32.00.

MGNX has been the subject of a number of recent research reports. Cowen reissued a “buy” rating on shares of MacroGenics in a research report on Wednesday, October 25th. Zacks Investment Research downgraded shares of MacroGenics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. ValuEngine raised shares of MacroGenics from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st. Raymond James Financial reissued a “buy” rating on shares of MacroGenics in a research report on Monday, December 11th. Finally, Citigroup boosted their price objective on shares of MacroGenics from $18.00 to $22.00 and gave the company a “neutral” rating in a research report on Friday, November 10th.

Shares of MacroGenics (NASDAQ:MGNX) traded up $1.08 during mid-day trading on Monday, hitting $20.53. 354,900 shares of the stock were exchanged, compared to its average volume of 170,144. MacroGenics has a 12-month low of $14.36 and a 12-month high of $22.31. The company has a market cap of $755.97, a P/E ratio of -4.56 and a beta of 2.73.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.19). MacroGenics had a negative net margin of 1,526.55% and a negative return on equity of 69.31%. The business had revenue of $1.70 million for the quarter, compared to the consensus estimate of $5.50 million. During the same period in the previous year, the firm earned ($0.97) EPS. The company’s revenue was down 48.5% on a year-over-year basis. equities research analysts expect that MacroGenics will post -0.7 earnings per share for the current year.

In related news, SVP Jon Marc Wigginton sold 5,000 shares of MacroGenics stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the transaction, the senior vice president now owns 35,000 shares in the company, valued at approximately $700,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 8.30% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in MGNX. Russell Investments Group Ltd. purchased a new position in shares of MacroGenics during the 2nd quarter valued at $133,000. Legal & General Group Plc lifted its stake in MacroGenics by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 328 shares in the last quarter. SG Americas Securities LLC lifted its stake in MacroGenics by 92.2% in the 2nd quarter. SG Americas Securities LLC now owns 10,812 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 5,187 shares in the last quarter. Parametric Portfolio Associates LLC purchased a new stake in MacroGenics in the 2nd quarter worth $203,000. Finally, Virtu KCG Holdings LLC purchased a new stake in MacroGenics in the 2nd quarter worth $232,000. Institutional investors own 85.77% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “MacroGenics Inc (MGNX) Receives Consensus Rating of “Buy” from Brokerages” was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/15/macrogenics-inc-mgnx-receives-consensus-rating-of-buy-from-brokerages.html.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.